[1]翟越,赵 卫,潘文秋,等.TACE联合载药微球治疗肝癌的研究进展[J].介入放射学杂志,2019,28(12):1211-1214.
　ZHAI Yue,ZHAO Wei,PAN Wenqiu,et al.TACE combined with drug- eluting beads for the treatment of hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2019,28(12):1211-1214.
点击复制

TACE联合载药微球治疗肝癌的研究进展()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
28
期数:
2019年12期
页码:
1211-1214
栏目:
综述
出版日期:
2019-12-28

文章信息/Info

Title:
TACE combined with drug- eluting beads for the treatment of hepatocellular carcinoma： recent progress in research
作者:
翟越;  赵 卫;  潘文秋;  张雪平;  陆 孜;  李 红;  胡继红
Author(s):
ZHAI Yue;  ZHAO Wei;  PAN Wenqiu;  ZHANG Xueping;  LU Zi;  LI Hong;  HU Jihong.
Department of Medical Imaging， First Affiliated Hospital of Kunming Medical University， Kunming， Yunnan Province 650032， China
关键词:
【关键词】 肝恶性肿瘤;  载药微球;  经导管动脉化疗栓塞
文献标志码:
A
摘要:
【摘要】 肝癌目前治疗的方法以外科切除和介入治疗为主，其中TACE已成为治疗中晚期不可切除肝癌的首选方法。载药微球作为一种新型栓塞材料，已广泛用于肝癌的TACE治疗，具有一定的安全性和有效性。与传统栓塞方法相比，载药微球能够降低全身化疗药物浓度、提高局部肿瘤药物浓度、延长药物作用时间、提高肿瘤的反应率，进而降低肿瘤的复发率、缩短住院时间、延长患者生存期。但载药微球的使用方法、术者操作技术，化疗药物的载入饱和量等差异，都可能对治疗结果产生影响。因此，载药微球的使用规范与治疗肝细胞癌的安全性与疗效，值得进一步研究。

参考文献/References:

［1］ Heimbach JK， Kulik LM， Finn RS， et al. AASLD guidelines for the treatment of hepatocellular carcinoma［J］. Hepatology， 2018， 67： 358- 380.
［2］ Facciorusso A， Licinio R, Muscatiello N， et al. Transarterial chemoem- bolization： evidences from the literature and applications in hepatocellular carcinoma patients［J］. World J Hepatol， 2015， 7： 2009-2019.
［3］ Nicolini D， Svegliati-Baroni G， Candelari R， et al. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembo-lization for hepatocellular carcinoma before liver transplantation［J］. World J Gastroenterol， 2013， 19： 5622-5632.
［4］ 金雪锋， 许 颖， 沈晓兰，等． 载药动脉栓塞微球DC BeadTM研究进展［J］． 药学与临床研究， 2012， 20： 319-325．
［5］ Varela M， Real MI， Burrel M， et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads： efficacy and doxorubicin pharmacokinetics［J］. J Hepatol， 2007， 46： 474-481.
［6］ Jiaqi Y， Hori S， Minamitani K， et al. A new embolic material： super absorbent polymer（SAP） microsphere and its embolic effects［J］. Nihon Igaku Hoshasen Gakkai Zasshi， 1996， 56： 19-24.
［7］ de Luis E， Bilbao JI， de Ciercoles JA， et al. In vivo evaluation of a new embolic spherical particle（HepaSphere） in a kidney animal model［J］. Cardiovasc Intervent Radiol， 2008， 31： 367-376.
［8］ 官泳松， 贺 庆， 靳 勇， 等． 迦俐生聚乙烯醇栓塞微球的研制［J］． 中华肝脏病杂志， 2016， 24： 549-551．
［9］ Zhang S， Huang C， Li Z， et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers［J］. Drug Deliv， 2017， 24： 1011-1017.
［10］ Imai N， Ishigami M， Ishizu Y， et al. Transarterial chemoembolization for hepatocellular carcinoma： a review of techniques［J］. World J Hepatol， 2014， 6： 844- 850.
［11］ Song MJ， Chun HJ， Song DS， et al. Comparative study between doxorubicin- eluting beads and conventional transarterial chemo- embolization for treatment of hepatocellular carcinoma［J］. J Hepatol， 2012， 57： 1244-1250.
［12］ Sacco R， Bargellini I， Bertini M， et al. Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma［J］. J Vasc Interv Radiol 2011； 22： 1545-1552.
［13］ Zurstrassen CE， Gireli LPO， Tyng CJ， et al. Safety and efficacy of HepaSphere 50-100 μm in the treatment of hepatocellular carcinoma［J］. Minim Invasive Ther Allied Technol， 2017， 26： 212-219.
［14］ Morimoto M， Kobayashi S， Moriya S， et al. Short- term efficacy of transarterial chemoembolization with epirubicin- loaded super-absorbent polymer microspheres for hepatocellular carcinoma： comparison with conventional transarterial chemoembolization［J］. Abdom Radiol（NY）， 2017， 42： 612- 619
［15］ Wu B， Zhou J， Ling G， et al. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma： a short-term efficacy and safety study［J］. World J Surg Oncol， 2018， 16： 69.
［16］ Zou JH， Zhang L， Ren ZG， et al. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma： a meta- analysis［J］. J Dig Dis， 2016， 17： 510- 517.
［17］ Chen P， Yuan P， Chen B， et al. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembo-lization in patients with unresectable hepatocellular carcinoma： a systematic review and meta- analysis［J］. Clin Res Hepatol Gastr- oenterol， 2017， 41： 75- 85.
［18］ Lee M， Chung JW， Lee KH， et al. Korean multicenter registry of transcatheter arterial chemoembolization with drug- eluting embolic agents for nodular hepatocellular carcinomas： six-month outcome analysis［J］. J Vasc Interv Radiol， 2017， 28： 502- 512.
［19］ Kucukay F， Badem S， Karan A， et al. A single- center retrospective comparison of doxorubicin-loaded hepasphere transarterial chemo-embolization with conventional transarterial chemoembolization for patients with unresectable hepatocellular carcinoma［J］. J Vasc Interv Radiol， 2015， 26： 1622-1629.
［20］ Malagari K， Chatzimichael K， Alexopoulou E， et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads： results of an open-label study of 62 patients［J］. Cardiovasc Intervent Radiol， 2008， 31： 269-280.
［21］ Malagari K， Pomoni M， Kelekis A， et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with beadblock for hepatocellular carcinoma［J］. Cardiovasc Intervent Radiol， 2010， 33： 541-551.
［22］ Wang B， Xu H， Gao ZQ， et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization［J］. Acta Radiol， 2008， 49： 523-529.
［23］ 刘 金， 曹 刚， 张根山， 等． 国产CalliSpheres载药微球治疗原发性肝癌12例［J］． 介入放射学杂志， 2017， 26： 993-998．
［24］ Xing M， Webber G， Prajapati HJ， et al. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoem-bolization for unresectable hepatocellular carcinoma： longitudinal prospective study［J］. J Gastroenterol Hepatol， 2015， 30： 1167-1174.
［25］ 王亚勋，吴宝林，周 军，等． 载药微球与空白微球栓塞治疗原发性肝癌的对比分析研究［J］． 影像诊断与介入放射学， 2017， 26： 445- 450．
［26］ Zuo MX， Huang JH. The history of interventional therapy for liver cancer in China［J］. J Intervent Med， 2018， 1： 70-76.
［27］ 赵 倩， 颜志平． 载药微球经导管动脉化疗栓塞治疗肝癌研究进展［J］． 介入放射学杂志， 2017， 26： 1052-1056．
［28］ Chen S， Yu W， Zhang K， et al. Comparison of the efficacy and safety of transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma［J］. BMC Cancer， 2018， 18： 1131.
［29］ Ikuta S， Aihara T. Efficacy of sequential sorafenib plus hepatic arterial infusion chemotherapy in patients with barcelona clinic liver cancer stage B and C hepatocellular carcinoma： a retrospective single-institution study［J］. Contemp Oncol（Pozn）， 2018， 22： 165-171.

相似文献/References:

[1]吴志远,丁晓毅,黄 蔚,等.门脉粒子支架联合载药微球栓塞治疗肝癌7例[J].介入放射学杂志,2017,(02):161.
　WU Zhiyuan,DING Xiaoyi,HUANG Wei,et al.Portal 125I seed stent implantation combined with drug-loaded microsphere embolization for the treatment of HCC： initial results in 7 patients[J].journal interventional radiology,2017,(12):161.
[2]赵 倩,颜志平.载药微球经导管动脉化疗栓塞治疗肝癌研究进展 [J].介入放射学杂志,2017,(11):1052.
　ZHAO Qian,YAN Zhiping.Transarterial chemoembolization with drug- eluting beads for the treatment of hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2017,(12):1052.
[3]李 鑫,李 臻,李 刚,等.载药微球化疗栓塞治疗下肢梭形细胞肉瘤1例[J].介入放射学杂志,2018,27(02):111.
　LI Xin,LI Zhen,LI Gang,et al.Successful treatment of lower limb spindle cell sarcoma by using chemoembolization with drug- eluting beads： report of one case[J].journal interventional radiology,2018,27(12):111.
[4]周 慷,魏梦蝶,石海峰,等.术中增强CT及全身麻醉下呼吸控制在特殊部位肝肿瘤射频消融中的应用 [J].介入放射学杂志,2018,27(09):860.
　ZHOU Kang,WEI Mongdie,SHI Haifeng,et al.The application of intraoperative enhanced CT scan and respiratory control under general anesthesia in radiofrequency ablation treatment of hepatic malignant tumors located at special regions[J].journal interventional radiology,2018,27(12):860.
[5]于 奇,吴 杰,高 飞,等.载药微球加载贝伐珠单抗治疗难治性实体瘤4例[J].介入放射学杂志,2019,28(01):81.
　YU Qi,WU Jie,GAO Fei,et al.HepaSphere loaded with bevacizumab for the treatment of refractory solid tumors： preliminary results in 4 patients[J].journal interventional radiology,2019,28(12):81.
[6]李亚华,段旭华,韩新巍,等.TACE术中应用三氧化二砷CalliSpheres载药栓塞微球治疗BCLC B期原发性肝癌13例 [J].介入放射学杂志,2019,28(03):232.
　LI Yahua,DUAN Xuhua,HAN Xinwei,et al.TACE by using arsenic trioxide drug- bearing CalliSpheres beads for the treatment of BCLC stage B HCC： preliminary results in 13 patients[J].journal interventional radiology,2019,28(12):232.
[7]刘冲,何金瞳,李天,等.水隔离技术对降低肝被膜下肿瘤微波消融术后残存的效果评价 [J].介入放射学杂志,2020,29(03):267.
　LIU Chong,HE Jintong,LI Tian,et al.Application of hydrodissection technique in reducing residual tumor tissue of hepatic subcapsular malignancy after microwave ablation and evaluation of its curative effect[J].journal interventional radiology,2020,29(12):267.
[8]翟 越,潘文秋,赵 卫,等.CalliSpheres联合阿帕替尼治疗肝癌的安全性和有效性[J].介入放射学杂志,2020,29(05):462.
　ZHAI Yue,PAN Wenqiu,ZHAO Wei,et al.The safety and effectiveness of CalliSpheres combined with apatinib for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2020,29(12):462.
[9]王舒婷,陈海波,施昌盛,等.经皮射频消融联合125I放射性粒子植入术治疗肝恶性肿瘤的疗效分析 [J].介入放射学杂志,2020,29(06):587.
　WANG Shuting,CHEN Haibo,SHI Changsheng,et al.Radiofrequency ablation combined with 125I radioactive seed implantation for the treatment of liver cancer： analysis of curative effect[J].journal interventional radiology,2020,29(12):587.
[10]荆 霞,徐 圣.Callispheres栓塞后综合征的综合护理模式与常规护理模式比较[J].介入放射学杂志,2020,29(07):722.
　JING Xia,XU Sheng..Comprehensive nursing mode versus routine nursing mode for post- embolization syndrome in HCC patients after DEB- TACE： a comparative study[J].journal interventional radiology,2020,29(12):722.
[11]张赛锋,邵国良.小粒径DEB- TACE治疗肝恶性肿瘤22例分析[J].介入放射学杂志,2023,32(07):667.
　ZHANG Saifeng,SHAO Guoliang..Small-sized drug-eluting beads TACE for hepatic malignant tumors： analysis of 22 cases[J].journal interventional radiology,2023,32(12):667.

备注/Memo

备注/Memo:
（收稿日期：2018-11-28）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2019-12-27